|
|
||||||||



,¶
Departments of*
Medicine, and
Microbiology and Immunology, Dartmouth College, Lebanon, NH 03756;
Baylor Institute for Immunology Research, Dallas, TX 75204;
Department of Medicine, Harvard Medical School and the Center for Immunology and Inflammatory Disease of the General Medical Services, Massachusetts General Hospital, Boston, MA 02114; and ¶ Veterans Affairs Medical Center, White River Junction, VT 05009
Tristetraprolin (TTP) is the only trans-acting factor shown to be capable of regulating AU-rich element-dependent mRNA turnover at the level of the intact animal; however, the mechanism by which TTP mediated RNA instability is unknown. Using an established model system, we performed structure/function analysis with TTP as well as examined the current hypothesis that TTP function is regulated by p38-MAPKAP kinase 2 (MK2) activation. Deletion of either the N- or C-terminal domains inhibited TTP function. Extensive mutagenesis, up to 16%, of serines and threonines, some of which were predicted to mediate proteasomal targeting, did not alter human TTP function. Mutation of the conserved MK2 phosphorylation sites enhanced human TTP function in both resting and p38-stress-activated protein kinase-MK2-activated cells. However, p38-stress-activated protein kinase-MK2 activation did not alter the activity of either wild-type or mutant TTP. TTP localized to the stress granules, with arsenite treatment reducing this localization. In contrast, arsenite treatment enhanced stress granule localization of the MK2 mutant, consistent with the involvement of additional pathways regulating this event. Finally, we determined that, in response to LPS stimulation, human TTP moves onto the polysomes, and this movement occurs in the absence of 14-3-3. Taken together, these data indicate that, although p38 activation alters TTP entry into the stress granule, it does not alter TTP function. Moreover, the interaction of TTP with 14-3-3, which may limit entry into the stress granule, is not involved in the downstream message stabilization events.
This article has been cited by other articles:
![]() |
R. M. Rowlett, C. A. Chrestensen, M. J. Schroeder, M. G. Harp, J. W. Pelo, J. Shabanowitz, R. DeRose, D. F. Hunt, T. W. Sturgill, and M. T. Worthington Inhibition of tristetraprolin deadenylation by poly(A) binding protein Am J Physiol Gastrointest Liver Physiol, September 1, 2008; 295(3): G421 - G430. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Jalonen, E.-L. Paukkeri, and E. Moilanen Compounds That Increase or Mimic Cyclic Adenosine Monophosphate Enhance Tristetraprolin Degradation in Lipopolysaccharide-Treated Murine J774 Macrophages J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 514 - 522. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Emmons, W.H. D. Townley-Tilson, K. M. Deleault, S. J. Skinner, R. H. Gross, M. L. Whitfield, and S. A. Brooks Identification of TTP mRNA targets in human dendritic cells reveals TTP as a critical regulator of dendritic cell maturation RNA, May 1, 2008; 14(5): 888 - 902. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Datta, R. Biswas, M. Novotny, P. G. Pavicic Jr., T. Herjan, P. Mandal, and T. A. Hamilton Tristetraprolin Regulates CXCL1 (KC) mRNA Stability J. Immunol., February 15, 2008; 180(4): 2545 - 2552. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Skinner, K. M. Deleault, R. Fecteau, and S. A. Brooks Extracellular Signal-regulated Kinase Regulation of Tumor Necrosis Factor-{alpha} mRNA Nucleocytoplasmic Transport Requires TAP-NxT1 Binding and the AU-rich Element J. Biol. Chem., February 8, 2008; 283(6): 3191 - 3199. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.S. Patil and K.L. Kirkwood p38 MAPK Signaling in Oral-related Diseases Journal of Dental Research, September 1, 2007; 86(9): 812 - 825. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. A. Khabar Rapid transit in the immune cells: the role of mRNA turnover regulation J. Leukoc. Biol., June 1, 2007; 81(6): 1335 - 1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sun, G. Stoecklin, S. Van Way, V. Hinkovska-Galcheva, R.-F. Guo, P. Anderson, and T. P. Shanley Tristetraprolin (TTP)-14-3-3 Complex Formation Protects TTP from Dephosphorylation by Protein Phosphatase 2a and Stabilizes Tumor Necrosis Factor-{alpha} mRNA J. Biol. Chem., February 9, 2007; 282(6): 3766 - 3777. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sauer, B. Schaljo, C. Vogl, I. Gattermeier, T. Kolbe, M. Muller, P. J. Blackshear, and P. Kovarik Interferons limit inflammatory responses by induction of tristetraprolin Blood, June 15, 2006; 107(12): 4790 - 4797. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Brook, C. R. Tchen, T. Santalucia, J. McIlrath, J. S. C. Arthur, J. Saklatvala, and A. R. Clark Posttranslational Regulation of Tristetraprolin Subcellular Localization and Protein Stability by p38 Mitogen-Activated Protein Kinase and Extracellular Signal-Regulated Kinase Pathways. Mol. Cell. Biol., March 1, 2006; 26(6): 2408 - 2418. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |